The Effects of Varenicline on Working Memory and Long-Term Potentiation in Non-Smokers with Schizophrenia
Year: 2015
Type: dissertation
Abstract: Background: Deficits in the nicotinic acetylcholine receptor (nAChR) system are proposed to underlie vulnerability to nicotine dependence and cognitive impairment in schizophrenia. Varenicline is a smoking cessation medication that enhances cognition in schizophrenia while treating nicotine dependence, possibly through the modulation of neuroplasticity. Methods: This study assessed the effects of varenicline (1 mg/day) versus placebo on neuroplasticity and working memory in 11 schizophrenia non-smokers and 11 non-smoker healthy subjects, to eliminate the confounding effects of tobacco smoking. Results: Patients with schizophrenia performed worse on the 3-back task compared to healthy subjects. Varenicline enhanced working memory in low-performers only, regardless of diagnosis. Deficits in neuroplasticity were found in patients with schizophrenia compared to healthy subjects, which were enhanced with varenicline compared to placebo. Conclusions: Varenicline may be a potential therapeutic option for the remediation of cognitive and neuroplasticity deficits in patients with schizophrenia regardless of smoking status.
Source: TSpace (University of Toronto)
Author: Alanna C. Bridgman
Institution: University of Toronto
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2609703870
